產(chǎn)品名稱

MDV 3100 - Enzalutamide

產(chǎn)品貨號(hào)

Axon 1613 CAS [915087-33-1] MF C21H16F4N4O2SMW 464.44 Purity: 99% Soluble in DMSO Description An orally active and very potent antagonist of androgen receptor (AR); Second-generation of antiandrogen for the treatment of advanced prostate cancer; highly recommended tool in AR research KEYWORDS:?MDV 3100 | Enzalutamide | 915087-33-1 | 915087-33-1 | AR antagonist | MDV3100 | Androgen | prostate cancer

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

MDV 3100 - Enzalutamide

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 1613

CAS [915087-33-1]

MF C21H16F4N4O2S
MW 464.44

Purity: 99%
Soluble in DMSO

MDV 3100

Description

An orally active and very potent antagonist of androgen receptor (AR); Second-generation of antiandrogen for the treatment of advanced prostate cancer; highly recommended tool in AR research

C Tran et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324 (5928), 787-790.?

C Harrison. Anticancer drugs: New approaches to anti-androgen activities. Nature Reviews Drug Discovery 2009, 8, 452-453.?

CJ Hoimes and WK Kelley. Redefining hormone resistance in prostate cancer. Ther. Adv. Med. Oncol. 2010, 2(2), 107–123.?

G Di Lorenzo et al. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70(8), 983-1000.

N Sharifi. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Exp. Opin. Invest. Drugs 2010, 19(7), 837-846.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Endocrinology Androgen (AR) NR3C

Androgen receptor (AR) antagonist

Chemical name

4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide

Parent CAS No.

[915087-33-1]

產(chǎn)品資料